A detailed history of Us Bancorp \De\ transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Us Bancorp \De\ holds 664 shares of AUTL stock, worth $1,447. This represents 0.0% of its overall portfolio holdings.

Number of Shares
664
Previous 1,382 51.95%
Holding current value
$1,447
Previous $4,000 50.0%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 28, 2024

SELL
$3.38 - $4.69 $2,426 - $3,367
-718 Reduced 51.95%
664 $2,000
Q2 2024

Aug 06, 2024

SELL
$3.33 - $5.68 $6 - $11
-2 Reduced 0.14%
1,382 $4,000
Q4 2023

Feb 09, 2024

BUY
$2.13 - $6.63 $2,947 - $9,175
1,384 New
1,384 $8,000
Q3 2022

Oct 27, 2022

BUY
$2.04 - $3.76 $15,610 - $28,771
7,652 New
7,652 $16,000
Q2 2022

Aug 01, 2022

SELL
$2.04 - $4.68 $614 - $1,408
-301 Closed
0 $0
Q1 2022

May 11, 2022

SELL
$3.52 - $5.46 $24,189 - $37,521
-6,872 Reduced 95.8%
301 $1,000
Q4 2021

Feb 11, 2022

BUY
$5.1 - $7.0 $13,877 - $19,047
2,721 Added 61.12%
7,173 $37,000
Q3 2021

Nov 10, 2021

BUY
$5.32 - $7.37 $15,295 - $21,188
2,875 Added 182.31%
4,452 $30,000
Q2 2021

Aug 05, 2021

BUY
$4.78 - $7.96 $4,340 - $7,227
908 Added 135.72%
1,577 $11,000
Q1 2021

Apr 28, 2021

BUY
$5.49 - $9.36 $713 - $1,216
130 Added 24.12%
669 $4,000
Q4 2020

Feb 04, 2021

SELL
$8.13 - $12.79 $3,504 - $5,512
-431 Reduced 44.43%
539 $5,000
Q3 2020

Nov 10, 2020

BUY
$11.64 - $16.3 $5,878 - $8,231
505 Added 108.6%
970 $11,000
Q2 2020

Aug 07, 2020

SELL
$5.38 - $16.14 $5,944 - $17,834
-1,105 Reduced 70.38%
465 $8,000
Q1 2020

May 13, 2020

BUY
$4.2 - $13.0 $5,577 - $17,264
1,328 Added 548.76%
1,570 $10,000
Q4 2019

Feb 04, 2020

BUY
$11.13 - $16.28 $2,693 - $3,939
242 New
242 $3,000

Others Institutions Holding AUTL

About Autolus Therapeutics plc


  • Ticker AUTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 90,909,800
  • Market Cap $198M
  • Description
  • Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...
More about AUTL
Track This Portfolio

Track Us Bancorp \De\ Portfolio

Follow Us Bancorp \De\ and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.